Basel is artificial intelligence hub
The canton of Basel-Stadt is one of the three largest Swiss technology clusters for advanced digitalization technologies, as the new Digitalization Atlas has revealed. It is especially strong in artificial intelligence, with Roche, in particular, filing many patents in this area.
Digitalization Atlas of Switzerland for the technology Artificial Intelligence (Image: EconSight)
The economic research and consulting company EconSight has published its latest Digitalization Atlas. In this, it examines the patent activities of companies in advanced digitalization technologies across the various regions of Switzerland, with the aim of highlighting where local technology clusters can be found.
According to the results, the canton of Basel-Stadt is one of the three largest clusters for advanced digitalization technologies in Switzerland. With these technologies, EconSight means artificial intelligence, encryption, big data, cloud computing and virtual reality. In total, companies and research facilities in the canton of Basel-Stadt have filed 202 patents in these areas.
According to the Digitalization Atlas, the technological focus of Basel-Stadt is artificial intelligence, with 75 percent of advanced digitalization patents within this field. This trend is above all driven by the Basel-based pharma giant Roche. In Switzerland, Roche holds the highest number of patents in artificial intelligence (115 patents). Roche is followed by Zurich technology company ABB (108 patents) and, by quite some margin, Google’s parent company Alphabet (40 patents).
Roche remains the clear leader even when all five technology categories are taken into account. With 149 patents, the Group ranks third behind the Western Swiss company Kudelski (213 patents) and ABB (196 patents).
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More